ADA 2023 Archives - Medical Design Sourcing

Dexcom CCO Teri Lawver says new sensor is ‘first step’ to expand addressable market

New Dexcom CCO Teri Lawver. [Image from Janssen Pharmaceutical Company website]Teri Lawver joined Dexcom (Nasdaq:DXCM) + as chief commercial officer just as the company got set for a massive commercial undertaking.

The FDA cleared the company’s next-generation Dexcom G7 continuous glucose monitor (CGM) in December 2022. One month later, Lawver assumed the position of CCO. Within about a month, she was set to oversee the U.S. launch of the G7.

A former Johnson & Johnson executive, Lawver became the first to serve in Dexcom’s newly created CCO role. As she assumed the position amid a crucial time for the company, she observed what makes Dexcom one of the leaders in the diabetes technology space — and potentially beyond.

“The first few months I’ve just reaffirmed the reasons that I joined Dexcom,” Lawver told Drug Delivery Business News. “It’s an unmatched opportunity for …

The biggest stories from the American Diabetes Association (ADA) 2023 Scientific Sessions

From left: the Insulet Omnipod 5, Medtronic MiniMed 780G and the Senseonics Eversense E3. These technologies were part of some of the biggest stories from the American Diabetes Associations’ 2023 Scientific Sessions. [Images courtesy of Insulet, Medtronic and Senseonics]As it does every year, this past week, the American Diabetes Association convened its Scientific Sessions to bring together leaders in the diabetes space.

At last year’s event, next-generation technologies from the big hitters took the spotlight. The 83rd iteration this past week produced a range of new studies, product updates and positive news for a range of technologies and innovations. From continuous glucose monitors (CGMs) to insulin pumps to digital platforms and diabetes reversal procedures, ADA 2023 saw it all.

Usual suspects, like Dexcom, Abbott, Medtronic and Insulet shared their updates. Meanwhile, promising data came out of Senseonics, Sernova, Bigfoot Biomedical and more.<…

Study shows health equity impact from Virta Health diabetes reversal platform

Virta Health announced that real-world data for its diabetes reversal platform demonstrated narrowing gaps in care.

The company shared its data at the American Diabetes Association’s 83rd Scientific Sessions. The research highlighted its impact on health equity. It demonstrated significant health improvement and medication reduction for members in the most and least disadvantaged U.S. neighborhoods.

Virta said diabetes disproportionately affects racial and ethnic minorities and those living in low-income areas. Additionally, those with financial hardships prove more likely to receive prescriptions for diabetes drugs that are older and harder to manage due to affordability and access. With complex regimens, these lower-income patients have a higher likelihood of hospitalization and severe diabetes complications.

Get the full story at our sister site, Drug Delivery Business News.

Vida Health reports positive data for virtual diabetes program in low-income populations

[Image courtesy of Vida Health]Vida Health announced new research demonstrating significantly lowered A1C levels with its virtual cardiometabolic program.

The research highlighted use of the program in low-income Medicare Advantage members. Significantly lowered A1C levels even occurred in areas with limited income and food access.

Vida Health’s study compared its members living in areas of low income and low access to food with members living elsewhere. The study classified such low-income areas using the USDA’s Food Access Research Atlas.

Results demonstrated that, irrespective of socioeconomic barriers, Vida interventions led to an average A1C reduction of -1.38 points.

Get the full story at our sister site, Drug Delivery Business News.

Studies back Fractyl Health diabetes reversal procedure, gene therapy

Fractyl Health announced multiple studies supporting its programs for the reversal and treatment of diabetes.

Lexington, Massachusetts-based Fractyl reported data from its Revitalize 1 pivotal study and its Rejuva program. Revitalize 1 evaluates the company’s Revita endoscopic ablation procedure to reverse diabetes. Rejuva evaluates a targeted pancreatic gene therapy.

The company presented its results at the American Diabetes Association’s 83rd Scientific Sessions.

Get the full story at our sister site, Drug Delivery Business News.

Data supports safety and accuracy of Senseonics 365-day CGM

The Eversense E3 system. [Image from Ascensia/Senseonics]Senseonics (NYSE: SENS) today announced positive clinical data highlighting the effectiveness of its Eversense continuous glucose monitor (CGM).

Germantown, Maryland–based Senseonics presented two studies on its latest-generation Eversense E3 at the American Diabetes Association 83rd Scientific Session. The 180-day implantable CGM received FDA approval in February of last year. The sensor is fully implantable and requires just two sensor insertion and removal procedures per year.

Senseonics’ latest data includes evidence supporting even longer wear time, plus more positive results for the existing platform.

“These data further bolster Eversense’s position as a leading CGM choice for people with diabetes,” said Dr. Francine Kaufman, Senseonics chief medical officer.

Get the full story at our sister site, Drug Delivery Business News.

Abbott, ADA partner on therapeutic nutrition program for people with diabetes

The FreeStyle Libre 3 continuous glucose monitor. [Image courtesy of Abbott]Abbott (NYSE: ABT) + and the American Diabetes Association (ADA) announced a collaboration to improve nutrition for people with diabetes.

The duo aims to help better understand how diabetes technology, like continuous glucose monitoring (CGM), can help. They hope to aid people with diabetes make more informed decisions about their food and activity.

Abbott develops a family of CGMs, the latest being the FreeStyle Libre 3. The company said that, over time, data from CGMs helps people with diabetes learn patterns and create a nutritional plan. That plan can help provide steady glucose levels and the potential for improved clinical outcomes, like lower A1C.

Get the full story at our sister site, Drug Delivery Business News.

Dexcom aims to bring new glucose sensor to the market for people who don’t use insulin

Dexcom (Nasdaq:DXCM) today unveiled its strategy to expand access to its glucose-sensing technology for millions around the world.

San Diego-based Dexcom held an Investor Day event in which it revealed plans to bring a new product to market in the U.S. in 2024. The company designed its new product for people who don’t use insulin — approximately 70% of Americans with diabetes.

Dexcom said it plans for its new product to feature a 15-day sensor and a cash-pay option. The company wants to offer a new software experience tailored for those not on insulin.

Earlier this year, Dexcom Chair, President and CEO, Kevin Sayer, hinted at potential new avenues when speaking to Drug Delivery Business News. He explained that the company wanted to broaden its focus, even revising its mission statement. Dexcom updated its mission — enabling people to take control of diabetes — by changing “diabetes” to “health.”

New data supports Medtronic MiniMed 780G automated insulin delivery system for children

The MiniMed 780G with Guardian 4 and a 7-day infusion set. [Image courtesy of Medtronic]Medtronic (NYSE: MDT) + today announced positive clinical and real-world data supporting its MiniMed 780G automated insulin delivery system.

The latest data sets evaluated the recently FDA-approved system across a wide range of users. They looked at younger patients, those not meeting glycemic goals and individuals using simplified meal announcement technology. Medtronic presented these results at the 83rd American Diabetes Association (ADA) Scientific Sessions in San Diego.

Among the findings, Medtronic reported positive results for its proprietary Meal Detection technology. MiniMed 780G is the only system with meal detection technology providing automatic adjustments and corrections to sugar levels every five minutes. This occurs for both basal (background) and bolus (mealtime) insulin needs.

Que Dallara, Medtronic Diabetes EV…